LIV-1/Zip6 Antibody [ADC] - (Ladiratuzumab Vedotin, Research Grade)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-44538
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
ADC
Antibody Source
Monoclonal Human IgG1
Concentration
LYOPH mg/ml
Product Specifications
Immunogen
LIV-1/Zip6 (Uniprot: Q13433)
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Theoretical MW
146.96 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Description
This product is an Antibody-Drug Conjugate (ADC) for Research Use Only (RUO).
Ladiratuzumab Vedotin is an ADC that combines a humanized anti-LIV-1 monoclonal antibody linked to a synthetic cytotoxic cell-disrupting agent, monomethyl auristatin E (MMAE)
This product is shipped at ambient temperature. Upon receipt, store immediately at -20C or lower for 12 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.
Ladiratuzumab Vedotin is an ADC that combines a humanized anti-LIV-1 monoclonal antibody linked to a synthetic cytotoxic cell-disrupting agent, monomethyl auristatin E (MMAE)
This product is shipped at ambient temperature. Upon receipt, store immediately at -20C or lower for 12 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.
Scientific Data Images for LIV-1/Zip6 Antibody [ADC] - (Ladiratuzumab Vedotin, Research Grade)
Flow Cytometry: Hu LIV-1/Zip6 mAb [ADC] - (Ladiratuzumab Vedotin) [NBP3-44538] -
Human LIV1 CHOS cells were stained with LIV-1/Zip6 (Ladiratuzumab Vedotin) Antibody and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.07456 ug/mL.Functional: Hu LIV-1/Zip6 mAb [ADC] - (Ladiratuzumab Vedotin) [NBP3-44538] -
The killing ratio LIV-1/Zip6 (Ladiratuzumab Vedotin) Antibody by Human LIV-1 HEK293 Cell Line increased with the increase of antibody concentration, and the killing Rate (%) reached 74%ELISA: Hu LIV-1/Zip6 mAb [ADC] - (Ladiratuzumab Vedotin) [NBP3-44538] -
Immobilized human LIV 1, His Tag at 2 ug/mL can bind LIV-1/Zip6 (Ladiratuzumab Vedotin) Antibody, EC50=0.007652 ug/mL.Applications for LIV-1/Zip6 Antibody [ADC] - (Ladiratuzumab Vedotin, Research Grade)
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
> 90% by SDS-PAGE and HPLC
Reconstitution
Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.
Formulation
Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)
Preservative
No Preservative
Concentration
LYOPH mg/ml
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C in powder form. Store at -80C once reconstituted.
Background: LIV-1/Zip6
Alternate Names
LIV-1, solute carrier family 39 (zinc transporter), member 6, zinc transporter ZIP6
Additional LIV-1/Zip6 Products
Product Documents for LIV-1/Zip6 Antibody [ADC] - (Ladiratuzumab Vedotin, Research Grade)
Product Specific Notices for LIV-1/Zip6 Antibody [ADC] - (Ladiratuzumab Vedotin, Research Grade)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...